Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955278 | 0.87 | TRPA1 (0.48) | ESR1ESR2TRPA1TSHR | |
| Hydrochloric Acid SCHEMBL5299628 | 0.85 | TRPA1 (0.46) | ESR1ESR2TRPA1TSHR | |
| SCHEMBL954845 | 0.79 | PTGS2 (0.48) | PTGS2CTSSCTSKCHRNB2CHRNA4 | |
| SCHEMBL17455465 | 0.77 | TSHR (0.48) | PTGS2ESR1ESR2CHRNB2CHRNA4 | |
| SCHEMBL11878426 | 0.76 | PTGS2 (0.46) | PTGS2ESR1ESR2CTSSCTSK | |
| SCHEMBL12019807 | 0.75 | ALOX5AP (0.39) | ESR1ESR2 | |
| SCHEMBL1193245 | 0.75 | CHRNB2 (0.42) | PTGS2ESR1ESR2CTSSCTSK | |
| SCHEMBL10952365 | 0.75 | ESR1 (0.47) | ESR1ESR2CTSSCTSK | |
| SCHEMBL10706998 | 0.75 | ESR1 (0.75) | ESR1ESR2 | |
| SCHEMBL7939324 | 0.75 | ESR1 (0.47) | ESR1ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496274-A | Fluorine-containing probe for distinguishing and detecting chiral analytes, preparation and application thereof | 中国科学院上海有机化学研究所 | 2024-08-16 | — | — | CN | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291988-A1 | Reversible Inhibitors of Monoamine Oxidase A and B | MAOB, MAOA, XDH | PTGS2 1499/4885ESR1 1417/4885ESR2 1622/4885 |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | PTGS2 2904/4885ESR1 4584/4885ESR2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.